SARS‐CoV‐2 vaccination response in pediatric oncology patients

Abstract

AbstractBackgroundThere remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination in pediatric oncology patients, which is essential to provide counseling and risk adaptation in this vulnerable population. The goal of this study was to understand immunogenicity after vaccination in pediatric oncology patients, and determine if certain clinical factors impacted response.MethodsPatients 0–25 years of age with a diagnosis of cancer and actively receiving therapy were enrolled on study. We excluded patients who were completely vaccinated prior to their cancer diagnosis. Blood samples were collected pre‐vaccination, as well as 2, 4–6, and 8–12 weeks after vaccination. Healthy children who were fully vaccinated enrolled as controls. Clinical data and complete blood counts around time of vaccination were collected. To study B‐ and T‐cell immunity, we measured neutralizing antibodies by enzyme‐linked immunoassay and interferon gamma secretion by enzyme‐linked immunospot, respectively.ResultsTwenty‐six patients enrolled on study, for which 11 were evaluable oncology patients and seven were healthy controls. Adequate B‐cell response was seen in 36.4% of patients, and adequate T‐cell response in 77.8% of patients. Numbers were too small to detect differences based on malignancy type. There was no differences in immunity based on absolute lymphocyte count (ALC) or intensity of therapy.ConclusionPediatric oncology patients have a suboptimal immune response to SARS‐CoV‐2 vaccination. Booster doses will be imperative to provide optimal protection against COVID‐19; however, blood counts may not be a useful guide to optimize the time of administration.